- Home
- TNGX vs FSBW Comparison
TNGX vs FSBW Comparison
Compare TNGX & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- FSBW
- Stock Information
- Founded
- TNGX 2014
- FSBW 1936
- Country
- TNGX United States
- FSBW United States
- Employees
- TNGX N/A
- FSBW N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- FSBW Banks
- Sector
- TNGX Health Care
- FSBW Finance
- Exchange
- TNGX Nasdaq
- FSBW Nasdaq
- Market Cap
- TNGX 723.2M
- FSBW 322.3M
- IPO Year
- TNGX N/A
- FSBW 2012
- Fundamental
- Price
- TNGX $7.87
- FSBW $42.35
- Analyst Decision
- TNGX Strong Buy
- FSBW Hold
- Analyst Count
- TNGX 6
- FSBW 1
- Target Price
- TNGX $10.00
- FSBW $44.00
- AVG Volume (30 Days)
- TNGX 1.7M
- FSBW 16.1K
- Earning Date
- TNGX 11-05-2025
- FSBW 10-21-2025
- Dividend Yield
- TNGX N/A
- FSBW 2.65%
- EPS Growth
- TNGX N/A
- FSBW N/A
- EPS
- TNGX N/A
- FSBW 4.15
- Revenue
- TNGX $24,296,000.00
- FSBW $139,676,000.00
- Revenue This Year
- TNGX $20.42
- FSBW $9.62
- Revenue Next Year
- TNGX N/A
- FSBW $5.35
- P/E Ratio
- TNGX N/A
- FSBW $10.19
- Revenue Growth
- TNGX N/A
- FSBW 0.61
- 52 Week Low
- TNGX $1.03
- FSBW $34.61
- 52 Week High
- TNGX $8.98
- FSBW $49.15
- Technical
- Relative Strength Index (RSI)
- TNGX 66.70
- FSBW 57.06
- Support Level
- TNGX $6.38
- FSBW $40.68
- Resistance Level
- TNGX $6.90
- FSBW $42.23
- Average True Range (ATR)
- TNGX 0.46
- FSBW 0.80
- MACD
- TNGX 0.09
- FSBW -0.10
- Stochastic Oscillator
- TNGX 90.50
- FSBW 77.67
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About FSBW FS Bancorp Inc.
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.